Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
Reason given: Due to the KoreaFDA issue
Key facts
- Phase
- Phase 1/2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Yae-Jean Kim
- Trial code
- NCT02346617
- Record updated
- 20 March 2020
- Original description
To evaluate the safety and efficacy for treatment of persistent CMV infection in hematopoietic cell transplant (HCT) recipients.Read full original descriptionShow less
Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection in Allogeneic Hematopoietic Cell Transplant Recipients
To evaluate the safety and efficacy for treatment of persistent CMV infection in hematopoietic cell transplant (HCT) recipients.
Inclusion: Less than 66 years old Allogeneic HCT recipients who received stem cells from related CMV positive serology donors; AND recipients have persistent CMV infection more than 2 weeks on antiviral treatment.
Exclusion: HCT recipients with severe graft versus host disease, grade 3 or more; OR organ dysfunction (brain, heart, lung, liver, and kidney): altered mentality, extracorporeal membrane oxygenation, mechanical ventilator, increased liver enzymes 5 times above upper normal values, bilirubin level >3 mg/dL, CrCl < 30 mL/min.